133
0 Kommentare
Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal
Hamilton, Bermuda, May 23, 2024 (GLOBE NEWSWIRE) -- HAMILTON, BERMUDA – May 23, 2024 -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”)
(Nasdaq:CYTO), a company dedicated to developing and commercializing RNA delivery technology for targets beyond the liver, today announced that highlights from the NASAR clinical trial with Bentrio
nasal spray in seasonal allergic rhinitis (SAR) have been published in video format on the social media channels of Allergy, one of the highest-ranking journals in the field of allergology
world-wide. This follows the journal’s publication in April of the peer-reviewed article “AM-301, a barrier-forming nasal spray, versus saline spray in seasonal allergic rhinitis: A randomized
clinical trial” which had provided detailed information about this pivotal trial. The video abstract is presented by Sven Becker, MD, the first author of the publication, and it is accessible
via:
YouTube: https://www.youtube.com/watch?v=Om8suFiQGcg&ab_channel=Allergy
Facebook: https://www.facebook.com/EAACIAllergy
Twitter: https://twitter.com/AllergyEaaci
LinkedIn: https://www.linkedin.com/company/allergy-eaaci
Allergy’s social media reaches out to over 250’000 readers every month, and there are more than two million downloads of their articles per year.
The NASAR trial enrolled 100 patients during allergy season in Australia who were randomized at a 1:1 ratio to receive either Bentrio or saline nasal spray, the current standard of care in drug-free SAR management. Study participants self-administered the treatment for two weeks three times per day. The study met its primary efficacy endpoint, showing a statistically significant reduction in the mean daily reflective Total Nasal Symptom Score (rTNSS) for Bentrio compared to saline (p = 0.013), as well as its secondary efficacy endpoints. The latter included, among others, a statistically significant improvement in health-related quality of life (Rhinoconjunctivitis Quality of Life Questionnaire, p < 0.001) and superior global ratings of efficacy by patients and investigators alike (p < 0.001). In addition, Bentrio showed good safety and tolerability, similar to saline controls, and fewer Bentrio treated patients used relief medication and more of them enjoyed symptom-free days compared to saline treatment.